Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 3.79 Billion | USD 5.90 Billion | 4.5% | 2023 |
Zion Market Research has published a report on the global H1N1 Vaccines Market, estimating its value at USD 3.79 Billion in 2023, with projections indicating that it will reach USD 5.90 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 4.5% over the forecast period 2024-2032. The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the H1N1 Vaccines Market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.
The report offers a valuation and analysis of the H1N1 Vaccines market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on value (USD Billion).
H1N1 flu virus is also termed swine flu and is called so when the individual comes in contact with pigs. In 2009, the swine flu pandemic was on the rampage, and people used to get ill after being infected with swine flu. According to WHO reported dated September 2009, H1N1 flu pandemic had resulted in more than 3 lac detected cases of H1NI flu and nearly 3,917 deaths across 191 nations. Reportedly, WHO had identified H1N1 flu vaccine to have favorable outcomes for the patients under clinical trials. Furthermore, vaccination is a key strategy for preventing and controlling influenza such as H1N1.
Moreover, the H1NI pandemic was first witnessed in California and Mexico and spread across the globe. For the record, WHO declared H1N1 flu a pandemic on 11th June 2009. As per NCBI, numerous cases of the disease were witnessed in young people and in the estimated age group in the range of 12 to 17 years in countries such as the UK, Canada, the U.S., Canada, Japan, and Chile. It was found that most of the persons affected due to the virus had infections of the upper respiratory tract, and nearly two to 5 percent required hospitalization. Furthermore, pregnant women were prone to a high risk of getting infected as per NIH researchers.
Most of the deaths were witnessed in patients aged between forty and fifty years of age. Additionally, it was decided by authorities of various affected countries to determine high-priority groups for inoculating H1N1 vaccines such as healthcare staff, young children, pregnant women, people affected due to heart or respiratory ailments, patients with an autoimmune disorder, and diabetics. A decision was made by authorities to manufacture a new H1N1 vaccine, although the inoculation program related to a seasonal vaccine for the H1N1 virus was carried out during 2009 – 2010.
The rise in the occurrence of H1N1 infection and reduction in the immunity of individuals along with fear of new H1N1 virus strains has enhanced the H1N1 vaccines market demand in recent years. Apparently, the rise in respiratory ailments with growing age and the surge in immunodeficient ailments will prop up the growth of H1N1 vaccines market over the years ahead. For the record, the U.S. Food and Drug Administration had given a green signal to various kinds of monovalent live attenuated vaccines, unadvanced influenza vaccines, and monovalent inactivated vaccines in September 2009. As per NIH researchers, in the U.S., nearly 81 million people were inoculated by the end of May 2010. NCBI has reported that the proportion of deaths and hospitalizations in the U.S. were avoided due to the administration of H1N1 vaccines through the 2009-2010 H1N1 flu vaccination program. All these aspects will further contribute to the enlargement of the market scope over the years ahead.
Furthermore, massive ongoing research activities in immunology and vaccine techniques along with aid & support from various globally renowned healthcare institutions will help in the creation & distribution of high-quality vaccines, thereby driving H1N1 vaccine market trends. With many vaccine producers emerging in countries such as India, China, and Thailand as well as countries in South America, the H1N1 vaccines industry is anticipated to witness accelerated growth in the coming decade. Growing awareness among patients about preventing swine flu and technological breakthroughs in the healthcare sector is projected to pave a way for market growth over the upcoming years.
The global H1N1 vaccines market is bifurcated on the basis of route of administration and regional analysis.
Based on the route of administration, the market is divided into intradermal vaccines, intranasal vaccines, and intramuscular vaccines.
Report Attributes | Report Details |
---|---|
Report Name | H1N1 Vaccines Market |
Market Size in 2023 | USD 3.79 Billion |
Market Forecast in 2032 | USD 5.90 Billion |
Growth Rate | CAGR of 4.5% |
Number of Pages | 110 |
Key Companies Covered | Baxter, Commonwealth Serum Laboratories, GlaxoSmithKline, Sanofi AG., Medimmune, AstraZeneca plc, Sinovac Biotech, Novartis, and Zydus Cadila |
Segments Covered | By route of administration, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America To Account Notably Towards Overall Market Revenue By 2032
The growth of the H1N1 vaccines industry in North American sub-continent over the projected timeframe is attributed to National Immunization Program started by the U.S. for inoculating people with H1N1 vaccines. In addition to this, various other government schemes started by the U.S. government to prevent H1N1 infection will further drive the regional market trends. Moreover, the presence of strong healthcare infrastructure facilities in the countries like Canada and the U.S. will steer the growth of H1N1 vaccines market in the sub-continent. Apart from this, the presence of giant players in the region along with technological upgradation in the vaccine domain has resulted in huge product penetration across the region in recent years.
Key participants profiled in the report are
By Route of Administration:
By Region
FrequentlyAsked Questions
Rise in the occurrence of H1N1 infection and reduction in the immunity of individuals along with fear of new H1N1 virus strain has enhanced the H1N1 vaccines market demand in the recent years. Apparently, rise in respiratory ailments with growing age and surge in immuno deficient ailments will prop up the growth of H1N1 vaccines market over the years ahead.
According to Zion market research report, the global H1N1 Vaccines Market, estimating its value at USD 3.79 Billion in 2023, with projections indicating that it will reach USD 5.90 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 4.5% over the forecast period 2024-2032.
North America is likely to make noteworthy contributions towards overall market revenue during forecast period. The regional market growth over 2024 – 2032 can be credited to National Immunization Program started by the U.S. for inoculating people with H1N1 vaccines.
The key players profiled in the report include Baxter, Commonwealth Serum Laboratories, GlaxoSmithKline, Sanofi AG., Medimmune, AstraZeneca plc, Sinovac Biotech, Novartis, and Zydus Cadila.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed